21
Views
7
CrossRef citations to date
0
Altmetric
Review

CRC screening: review of the evidence and suggestions on when and how to move on from randomized trials to screening programmes

Pages 99-103 | Published online: 08 Jul 2009

References

  • http://www-dep.iarc.fr/globocan/globocan.html.
  • Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps. Cancer 2002;95:1618–25.
  • Svensson E, Grotmol T, Hoff G, Langmark F, Norstein J, Tretli S. Trends in colorectal cancer incidence in Norway by gender and anatomic site: an age-period-cohort analysis. Eur J Cancer Prev 2002;11:489–95.
  • Butruk E, Regula J, Polkowski M, et al. National colorectal cancer screening programme in Poland. Endoscopy 2002;34: 939–40.
  • http://europa.eu.int/comm/health/ph_determinants/genetics/keydo_genetics_en.htm.
  • WHO Executive Summary: National Cancer Control Programmes, Policies and managerial guidelines, 2nd ed. WHO; 2002.
  • Norwegian Centre for Medical Technology Assessment, Screening for colorectal cancer. SMM report no. 3/2001. In Norwegian.
  • Wang H, Kåresen R, Hervik A, etal. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 2001;12:39–45.
  • Mandel JS, Bond J, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365–71.
  • Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472–7.
  • Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467–71.
  • Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157–68.
  • Kronborg O. Screening for colorectal cancer in the average-risk population. Sem Colon Rect Surg 2002;13:16–30.
  • Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003;62:316–21.
  • Robinson MHE, Hardcastle JD, Moss SM, Amar SS, Chamberlain JO, Armitage NCM, et al. The risks of screening: data from the Nottingham randomized controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999;45:588–92.
  • Liebermann DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555–60.
  • UK Flexible Sigmoidoscopy Screening Trial Investigators, Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359:1291–300.
  • Segnan N, Senore C, Andreoni B, et al. Baseline findings in the Italien multicenter randomised controlled trial of ‘once-only sigmoidoscopy’-SCORE. JNCI 2002;94:1763–72.
  • Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years. Scand J Gastroenterol 2003;38:635–42.
  • Bretthauer M, Gondal G, Larsen IK, Carlsen E, Eide TJ, Grotmol T, et al. Design, organisation and management of a controlled population screening study for detection of colorectal neoplasia. Attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol 2002;37:568–73.
  • Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999;34:414–20.
  • Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983–1996. Eur J Cancer Prev 2001;10: 131–7.
  • Tymstra T, Bieleman B. The psychosocial impact of mass screening for cardiovascular risk factors. Fam Pract 1987;4:287–90.
  • Hoff G, Vatn M, Gjone E, Larsen S, Sauar J. Epidemiology of polyps in the rectum and sigmoid colon. Design of a population screening study. Scand J Gastroenterol 1985;20:351–5.
  • Wardle J, Taylor T, Sutton S, Atkin W. Does publicity about cancer screening raise fear of cancer? Randomised trial of the psychological effect of information about cancer screening. Br Med J 1999;319:1037–8.
  • Thiis-Evensen E, Wilhelmsen I, Hoff GS, Blomhoff S, Sauar J. The psychologic effect of attending a screening program for colorectal polyps. Scand J Gastroenterol 1999;34:103–9.
  • Hosokawa O, Shirasaki S, Kaizaki Y, Hayashi H, Douden K, Hattori M. Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 2003;35:506–10.
  • Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329: 1977–81.
  • Carter S, Winslet M. Delay in the presentation of colorectal carcinoma: a review of causation. Int J Colorectal Dis 1998; 13: 27–31.
  • Langenbach MR, Schmidt J, Neumann J, et al. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg 2003; 27:304–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.